They are not magic
Both Lilly and Novo are also trying to improve health insurance coverage of GLP-1 drugs for weight loss
In this article, well explore the potential of GLP-1 patches, how they might fit into the broader treatment landscape, and what patients considering metabolic health support should know about the future of these therapies
And our current thinking about obesity, and one of the components of the disease of obesity, is that some individuals although they all have GLP-1 and these other gut hormones, amylin, glucagon, GIP, that's what they're called that signal, for some reason, is not getting to the brain in ample amounts to tell the individual to feel full, satiated, and stop eating
confirm the current figure with the linked source before you buy